WILMINGTON, Mass., March 27, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced the appointment of Jonathan Saunders into the newly created position of Manufacturing Manager. Mr. Saunders will report to Brenda Baron, Vice President of Manufacturing Operations.
"In fiscal 2013, we shipped more ETDs than in any other year in our Company's history, a trend we expect will continue. We believe that the regulatory approvals we've recently received will prove to be key drivers of growth. Having moved into our new 58,000 square foot state-of-the-art manufacturing facility last summer, we now have the capacity to produce the quantities necessary to meet our expected future demand," stated Implant Sciences' Chief Operating Officer, Dr. Bill McGann. "Jon is an important hire for our company to support this rapid growth in manufacturing."
"We welcome Jon, who has a strong track record of managing high-tech manufacturing for companies with rapid revenue and production growth. We believe that his experience will be valuable in his position as Manufacturing Manager. As the only American-owned ETD manufacturer to have product qualification from the TSA, we are proud of our commitment to manufacture in the USA," added Brenda Baron, Vice President of Manufacturing Operations.
Mr. Saunders' expertise is in managing growing manufacturing operations with a focus on driving efficiency and profitability. He was most recently Plant Manager at EIT Northeast Operations, a manufacturer of printed circuit board assemblies (PCBAs) and complex system assemblies, where he managed a 40% revenue increase. Prior, he served for ten years in several positions with Sanmina-SCI, a global contract manufacturer of top level electronic assemblies. He was Vice President of Operations at Sanmina-SCI's Woburn, Massachusetts plant, and Plant Manager of the company's Manchester, New Hampshire facility, where he oversaw a significant increase in revenues as well as increased labor efficiencies. Mr. Saunders has also served as Plant Manager for Mack Technologies, Operations Manager for Bull Electronics, and Manufacturing Manager for Teledyne Electro-Mechanisms.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at http://www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; our business is subject to intense competition and rapid technological change, and our success will depend on our ability to develop and introduce new products; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation